Okwangoku, inkampani igqibile ukwenza umsebenzi ochaphazelekayo weSigaba II sophando lweklinikhi kunye nolungiselelo lweSigaba sesithathu sovavanyo lweklinikhi ye-Albenatide. Ngokweziphumo zokuqala zokuvavanywa kweklinikhi kunye neemfuno zokuvunywa kwezonyango ngenaliti ye-Albenatide, kudityaniswa nemeko eyiyo yenkampani, inkampani ikholelwa ukuba sele inemibandela yokuqalisa ulingo lwezonyango lwe-III kwaye ithatha isigqibo sokuqala isigaba se-III soklinikhi. .
I-Albenatide yiklasi eyi-1,1 kunyango lwesifo seswekile yesibini. Yinto yokulungiselela ukuhlala ixesha elide ye-GLP-1 ye-receptor agonist enokulimala kanye ngeveki, okuphucula kakhulu ukuthotyelwa kwesigulana ngonyango.

Inkampani yaqhuba isigaba sokuqala seKlinikhi yokuvavanywa kwenaliti yeAlbenatide kwisibhedlele sokuqala seYunivesithi yaseJilin, kunye novavanyo lweklinikhi lwesigaba sesibini lwe-Albenatide II kwizibhedlele ezingama-28 kubandakanywa nesibhedlele sasePeking University. Emva kovavanyo lweklinikhi lwesigaba sesibini lwe-Albenatide Injection lugqitywe nge-7 kaJuni ngo-2019, inkampani yaqhuba uhlalutyo lwamanani kunye nokudibana kwedatha efanelekileyo yophando. Ukuza kuthi ga ngoku, inkampani igqibe isigaba sesibini sophando lweklinikhi olunxulumene nenaliti yeAlbenatide. Iziphumo zesigaba II sokuvavanywa kweklinikhi yenaliti yeAlbenatide yabonisa ukuba ufikeleleko oluphambili lwesigaba II solingo.